Some *Staphylococcus aureus* strains remain susceptible to penicillin G (Pc), although resistance rapidly emerged after introducing Pc. According to the Japan Nosocomial Infections Surveillance report in 2015 (<http://www.nih-janis.jp/>), 43.8% of 119,343 methicillin-susceptible *S. aureus* (MSSA) isolates from all registered medical institutes were susceptible to Pc. Thus, this antimicrobial agent remains the treatment of choice for patients infected with Pc-susceptible isolates, as Pc is considered superior to oxacillin against penicillinase-negative isolates. Reliable detection of penicillinase production is important, but the detection and reporting of Pc susceptibility and resistance remains difficult.

Two mechanisms contribute to Pc resistance in *S. aureus*; first, involving the production of penicillinase encoded by *blaZ*, which can inactivate Pc by hydrolyzing the β-lactam ring \[[@B1]\], and second, involving an altered Pc-binding protein, PBP2a, encoded by *mecA* \[[@B2][@B3]\]. *blaZ* is an 846-bp gene controlled by two regulatory genes (antirepressor *blaR1* and repressor *blaI*) \[[@B3]\]. After exposure to β-lactams, *blaR1* (transmembrane sensor--transducer) undergoes autocatalytic cleavage, promoting the cleavage of *blaI* and leading to the transcription of *blaZ* \[[@B1][@B4]\]. Serotype analysis has reported four types (Ambler class A) of penicillinase: A, C, and D are located on plasmids, while B is located on the chromosome \[[@B5][@B6]\].

Guidelines of the CLSI and European Committee on Antimicrobial Susceptibility Testing (EUCAST) recommend that microbiological laboratories perform phenotypic tests (nitrocefin-based test and Pc 10-U \[P10\] or 1-U \[P1\] zone edge tests) to detect penicillinase in *S. aureus* strains \[[@B7][@B8]\]. Nitrocefin-based tests are reportedly less sensitive than Pc-disc zone edge determinations \[[@B9][@B10][@B11]\]. This study aimed to assess the prevalence of *blaZ* and performance of various phenotypic tests using *S. aureus* isolates from Japan.

We prospectively collected and randomly selected non-duplicate 200 MSSA isolates with Pc minimum inhibitory concentrations (MICs) of ≤0.12 µg/mL (breakpoint judged as susceptible to Pc) based on the CLSI broth microdilution (BMD) method with the MicroScan WalkAway System (Beckman Coulter Inc., Tokyo, Japan) at one laboratory (Byotai-Seiri Laboratory), from June 2015 through January 2016 \[[@B7]\]. Patient information (including gender, age, and clinical specimens) was recorded. We performed six phenotypic tests (nitrocefin-based test, P10 zone edge test/P10 diffusion test, Pc 2-U \[P2\] zone edge test/P2 diffusion test, and cloverleaf test) for each screened isolate. P2 was applied as the minimum U of Pc because the recommended P1 was not available in Japan. Briefly, a BBL Cefinase Paper disc (Becton, Dickinson and Company, Tokyo, Japan) was used in the nitrocefin-based test \[[@B7]\]. This test was conducted using inoculum directly from the margin zone surrounding a cefoxitin disc (30 µg) placed on Mueller-Hinton agar (MHA) after 16--18 hours of incubation to induce penicillinase production in the isolates. When the disc showed a pink color at room temperature (approximately 20℃) within 1 hour of the reaction, the isolate was considered penicillinase-positive. Two different disc diffusion tests were performed on MHA by applying both P10 (BD Sensi-Disc, Becton, Dickinson and Company) and P2 (SP Check, Nissui Pharmaceutical Co., Ltd., Tokyo, Japan). P10 zone diameters were interpreted according to the CLSI criteria (isolates with a P10 diameter of ≤28 mm were considered resistant) \[[@B7]\], and P2 zone diameters were interpreted according to the EUCAST criteria (isolates with a P1 diameter of ≤25 mm were considered resistant) \[[@B8]\]. The Kirby--Bauer Pc disc diffusion zone of inhibition was virtually assessed as "sharp" or "fuzzy" \[[@B7]\]. A "sharp" edge at the inhibition zone around the disc suggested penicillinase production, whereas a "fuzzy" edge suggested no production. Both the zone diameter and appearance of the zone edge were recorded independently by two investigators. The cloverleaf test was also conducted to detect penicillinase \[[@B10]\]. Any deviation from a complete circle was considered positive for penicillinase. All isolates were stored at −80℃ until genetic analyses. The study protocol was examined and approved by the committee of the institution (Byotai-Seiri Laboratory).

After completing the phenotypic tests, all the stored isolates were sent to one laboratory (Kitasato Institute for Life Sciences) for further analyses. Two different primer sets of stau-*blaZ*-fwd/stau-*blaZ*-rev 488 were used to amplify *blaZ* by PCR from a mixture of 100--200 ng of extracted genomic DNA \[[@B10]\]. PCR by stau-*blaZ*-fwd/stau-*blaZ*-rev was selected as the standard, as there were no mutations in its primer sequences and the amplicon generated by this set was within the *blaZ* coding region. Amplification products (421-bp and 674-bp) were resolved on a 1.5% agarose gel, stained with ethidium bromide, and visualized using an ultraviolet transilluminator. We also confirmed the correct sequences of the amplicons of all positive isolates by PCR. ATCC 29213 (penicillinase-positive) and ATCC 25923 (penicillinase-negative) were used as quality control strains for the BMD method, phenotypic tests, and PCR methods \[[@B11]\].

Two hundred isolates were recovered from 13 sterile specimens (11 blood/1 joint fluid/1 pleural effusion) and 187 non-sterile specimens (120 respiratory tract-origin/52 skin-origin/14 urine/1 stool) of patients (109 men/91 women; median age 76 years, range 0--102 years). The relationship between phenotypic test data and *blaZ* PCR results is shown in [Table 1](#T1){ref-type="table"}. All isolates showed Pc MICs of ≤0.03 µg/mL based on the CLSI BMD method \[[@B7]\]. The isolates excluded from [Table 1](#T1){ref-type="table"} showed negative results for the six phenotypic tests and two *blaZ* PCR methods. We observed only two *blaZ*-positive isolates (No. 28 and 33) with correct sequences, which were amplified by both primer sets stau-*blaZ*-fwd/stau-*blaZ*-rev and 486/488 ([Table 1](#T1){ref-type="table"}).

Sensitivity, specificity, and positive and negative predictive values of phenotypic tests using *blaZ* PCR as the standard are indicated in [Table 2](#T2){ref-type="table"}. We found a low sensitivity (50%) and positive predictive value (PPV, 50%) of the nitrocefin-based test, low PPV (18.2%) of the P10 zone edge test, low sensitivity (50%) of the P10 diffusion test, low PPV (50% and 22.2%) of the P2 zone edge test and P2 diffusion test, and low sensitivity (50%) of the cloverleaf test.

[Table 3](#T3){ref-type="table"} summarizes the prevalence of *blaZ* among *S. aureus* isolates, various primer sets to amplify *blaZ*, and different amplicon sizes, used in previous studies and the current study \[[@B9][@B10][@B11][@B12][@B13][@B14][@B15]\]. *blaZ* prevalence in Japan (2.7%, 3.5%, and 1%) was lower than that observed in Germany, the United States, Australia, and Switzerland (14.2%, 9.5%, 24.2%, and 40.9%, respectively), although it remains unclear why the prevalence was low in Japan. The use of only one PCR primer set and lack of amplicon sequencing may have caused false-positive or false-negative results because of polymorphisms within the *blaZ* sequence (including the PCR primer sequence regions) \[[@B5][@B16]\] or targeting a genetic region peripheral to *blaZ* \[[@B10]\]. False-positive results are induced by non-functional mutant genes that are inadequately counted, and false-negative results occur when functional mutant genes are missed \[[@B11]\]. Therefore, we applied two primer sets for sequencing.

In conclusion, these data suggest the low performance (sensitivity and PPV) of the six phenotypic tests because of the low prevalence (1%) of *blaZ* in *S. aureus* isolates from Japan. The decreased sensitivities of the phenotypic tests in this study may be related to the use of a highly selective collection of isolates, all of which had low Pc MICs (≤0.03 µg/mL). Therefore, additional studies on isolates with borderline MICs (0.06 and 0.12 µg/mL) are needed.
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###### Relationship between results of phenotypic penicillinase tests and *blaZ* PCR as the standard
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  Isolate No.   Time of isolation (year/month)   Source                Nitrocefin-based test   P2 zone inhibition test (mm)^\*^   P2 zone edge test   P10 zone inhibition test (mm)^†^   P10 zone edge test   Cloverleaf test   *blaZ* PCR using primer set stau-*blaZ*-fwd/stau-*blaZ*-rev   *blaZ* PCR using primer set 486/488
  ------------- -------------------------------- --------------------- ----------------------- ---------------------------------- ------------------- ---------------------------------- -------------------- ----------------- ------------------------------------------------------------- -------------------------------------
  2             2015/Jun                         Pus                   \-                      24 (R)                             Fuzzy               44 (S)                             Fuzzy                \-                \-                                                            \-
  3             2015/Jun                         Sputum                \-                      25 (R)                             Fuzzy               40 (S)                             Fuzzy                \-                \-                                                            \-
  6             2015/Jun                         Skin                  \-                      25 (R)                             Fuzzy               44 (S)                             Fuzzy                \-                \-                                                            \-
  8             2015/Jun                         Periunguinal region   \-                      25 (R)                             Fuzzy               42 (S)                             Fuzzy                \-                \-                                                            \-
  10            2015/Jun                         Sputum                \-                      25 (R)                             Fuzzy               39 (S)                             Fuzzy                \-                \-                                                            \-
  16            2015/Jul                         Pus                   \-                      25 (R)                             Fuzzy               44 (S)                             Fuzzy                \-                \-                                                            \-
  28            2015/Jul                         Sputum                \-                      25 (R)                             Sharp               32 (S)                             Sharp                \-                \+                                                            \+
  31            2015/Jul                         Pus                   \-                      31 (S)                             Fuzzy               44 (S)                             Sharp                \-                \-                                                            \-
  33            2015/Jul                         Sputum                \+                      15 (R)                             Sharp               20 (R)                             Sharp                \+                \+                                                            \+
  63            2015/Jul                         Decubitus             \-                      31 (S)                             Fuzzy               37 (S)                             Sharp                \-                \-                                                            \-
  65            2015/Jul                         Sputum                \-                      31 (S)                             Fuzzy               37 (S)                             Sharp                \-                \-                                                            \-
  79            2015/Aug                         Ear discharge         \-                      31 (S)                             Sharp               34 (S)                             Sharp                \-                \-                                                            \-
  85            2015/Sep                         Stool                 \-                      32 (S)                             Sharp               37 (S)                             Sharp                \-                \-                                                            \-
  88            2015/Sep                         Blood                 \-                      40 (S)                             Fuzzy               46 (S)                             Sharp                \-                \-                                                            \-
  93            2015/Sep                         Sputum                \-                      31 (S)                             Fuzzy               36 (S)                             Sharp                \-                \-                                                            \-
  95            2015/Sep                         Blood                 \-                      31 (S)                             Fuzzy               37 (S)                             Sharp                \-                \-                                                            \-
  121           2015/Oct                         Pus                   \-                      32 (S)                             Fuzzy               40 (S)                             Sharp                \-                \-                                                            \-
  178           2015/Dec                         Sputum                \-                      22 (R)                             Fuzzy               31 (S)                             Fuzzy                \-                \-                                                            \-
  187           2015/Dec                         Skin                  \+                      30 (S)                             Fuzzy               42 (S)                             Fuzzy                \-                \-                                                            \-
  ATCC 25923    NA                               NA                    \-                      28 (S)                             Fuzzy               34 (S)                             Fuzzy                NA                \-                                                            \-
  ATCC 29213    NA                               NA                    \+                      17 (R)                             Sharp               19 (R)                             Sharp                \+                \+                                                            \+

ATCC 25923 and ATCC 29213 were applied as penicillinase-negative and -positive controls, respectively.

^\*^P2 zone diameters were interpreted according to the EUCAST criteria (isolates with P1 diameter of ≤25 mm were considered resistant) \[[@B11]\], and its interpretations are given in parentheses; ^†^P10 zone diameters were interpreted according to the CLSI criteria (isolates with P10 diameter of ≤28 mm were considered resistant) \[[@B11]\], and its interpretations are given in parentheses.

Abbreviations: R, resistant; S, susceptible; NA, not applicable; +, positive; −, negative.

###### Sensitivity, specificity, and positive and negative predictive values of penicillinase tests using *blaZ* PCR as the standard
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  Penicillinase test                    Sensitivity (%)   Specificity (%)   Positive predictive value (%)   Negative predictive value (%)
  ------------------------------------- ----------------- ----------------- ------------------------------- -------------------------------
  Nitrocefin-based test                 50                99.5              50                              99.5
  P2 zone diameter interpretation^\*^   100               96.5              22.2                            100
  P2 zone edge test                     100               99                50                              100
  P10 zone diameter interpretation^†^   50                100               100                             99.5
  P10 zone edge test                    100               95.5              18.2                            100
  Cloverleaf test                       50                100               100                             99.5

^\*^P2 zone diameters were interpreted according to the EUCAST criteria (isolates with a P1 diameter of ≤25 mm were considered resistant) \[[@B11]\]; ^†^P10 zone diameters were interpreted according to the CLSI criteria (isolates with a P10 diameter of ≤28 mm were considered resistant) \[[@B11]\].

###### Prevalence of *blaZ* among *Staphylococcus aureus* isolates in previous reports and the current study
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  Year of report (reference)   Country of isolation (total N of collected isolates)   Percentage (%) of *blaZ* gene prevalence among all isolates   Primer set used to amplify *blaZ*                     Amplicon size (bp)
  ---------------------------- ------------------------------------------------------ ------------------------------------------------------------- ----------------------------------------------------- --------------------
  2008 \[[@B9]\]               Germany (197)                                          14.2                                                          stau-*blaZ*-fwd/stau-*blaZ*-rev                       421
  2011 \[[@B12], [@B13]\]      Japan (450)                                            2.7                                                           stau-*blaZ*-fwd/stau-*blaZ*-rev                       421
  2012 \[[@B10]\]              United States (105)                                    9.5                                                           stau-*blaZ*-fwd/stau-*blaZ*-rev, 487/373, & 486/488   421, 377, & 674
  2014 \[[@B11]\]              Australia (157)                                        24.2                                                          blaZ-F/blaZ-R                                         326
  2014 \[[@B14]\]              Japan (170)                                            3.5                                                           ND                                                    ND
  2017 \[[@B15]\]              Switzerland (215)                                      40.9                                                          *blaZ*-fwd/*blaZ*-rev & blaZ F1/blaZ R1               418 & 533
  This report                  Japan (200)                                            1                                                             stau-*blaZ*-fwd/stau-*blaZ*-rev & 486/488             421 & 674

Abbreviation: ND, not described.
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